Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy.
about
Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptanceCanadian hereditary angioedema guideline.A consensus parameter for the evaluation and management of angioedema in the emergency department.WAO Guideline for the Management of Hereditary AngioedemaIn pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency.High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational studyUse of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International Berinert® (C1-INH) Registry.Expert perspectives on hereditary angioedema: Key areas for advancements in care across the patient journeyProgress in the emergency management of hereditary angioedema: focus on new treatment options in the United States.Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency.How we manage persons with hereditary angioedema.A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).Hereditary angioedema: children should be considered for training in self-administration.C1 inhibitor concentrate treatment of multiple laryngeal attacks in a 53-year-old woman with hereditary angioedema.Hereditary Angioedema: The Economics of Treatment of an Orphan Disease.
P2860
Q28079761-8FE28B37-EF3B-4535-8241-798ABE00D112Q30596332-CE21FD3A-67A2-4F3C-848F-26CAADF667EEQ33909577-F279D5AE-35AE-44CB-8091-6BFB57224086Q36834816-88DD44CD-FD97-4F9C-B4DF-609862D3438FQ36960231-96816E65-2E52-4B4A-9C82-50B196D414E7Q37299151-E8D4A093-104B-4D3F-9516-474939E7A179Q37410712-C7DF47CA-201A-41BF-B47B-2A895D7AE2DEQ37593088-EF448E92-7480-4F32-800D-7FAC7D42A7F0Q38018214-70090974-1518-4FEA-A852-BD5DE583CD0CQ38103288-05F295FD-6986-40B5-B469-4DA6BB77A0CCQ38806437-2946590B-2ACA-4AB2-B8D6-B2E19E1CE79CQ38840241-5819E451-2B77-471E-B90F-278D2CACA51DQ39201379-BC265FF2-AE23-44A6-BACE-63322937980DQ39227947-0348D860-4F2B-440B-BD70-2899A9A86062Q50350621-5D6EC542-68A5-4ADF-B30F-165E772071C2
P2860
Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Safety and efficacy of physici ...... inhibitor replacement therapy.
@ast
Safety and efficacy of physici ...... inhibitor replacement therapy.
@en
type
label
Safety and efficacy of physici ...... inhibitor replacement therapy.
@ast
Safety and efficacy of physici ...... inhibitor replacement therapy.
@en
prefLabel
Safety and efficacy of physici ...... inhibitor replacement therapy.
@ast
Safety and efficacy of physici ...... inhibitor replacement therapy.
@en
P2093
P2860
P356
P1476
Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy
@en
P2093
Anthony J Castaldo
Donna K Davis
James Koziol
Louanne M Tourangeau
Sandra C Christiansen
P2860
P304
P356
10.1159/000329635
P577
2011-11-25T00:00:00Z